EJC SUPPLEMENTS 12 (2014) 41–53

Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejcancer.com

Sexual dysfunction and infertility as late effects of cancer treatment

Leslie R. Schover [a,*], *Marleen van der Kaaij* [b], *Eleonora van Dorst* [c], *Carien Creutzberg* [d], *Eric Huyghe* [e], *Cecilie E. Kiserud* [f]

[a] *Department of Behavioral Science, Unit 1330, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA*
[b] *Department of Internal Medicine, ZH 4A 35, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands*
[c] *Department of Reproductive Medicine and Gynaecological Oncology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands*
[d] *Department of Clinical Oncology, Leiden University Medical Center, K1-P, Albinusdreef 2, 2333 ZA Leiden, The Netherlands*
[e] *Service d'Urologie et d'Andrologie, Hopital Rangueil, 1, avenue Jean Poulhes, TSA 50032, 31059 Toulouse Cedex 9, France*
[f] *National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway*

ARTICLE INFO

Article history:
Received 26 March 2014
Accepted 26 March 2014

Keywords:
Oncology
Late effects
Sexuality
Sexual dysfunction
Oncofertility
Fertility preservation

ABSTRACT

Sexual dysfunction is a common consequence of cancer treatment, affecting at least half of men and women treated for pelvic malignancies and over a quarter of people with other types of cancer. Problems are usually linked to damage to nerves, blood vessels, and hormones that underlie normal sexual function. Sexual dysfunction also may be associated with depression, anxiety, relationship conflict, and loss of self-esteem. Innovations in cancer treatment such as robotic surgery or more targeted radiation therapy have not had the anticipated result of reducing sexual dysfunction. Some new and effective cancer treatments, including aromatase inhibitors for breast cancer or chemoradiation for anal cancer also have very severe sexual morbidity. Cancer-related infertility is an issue for younger patients, who comprise a much smaller percentage of total cancer survivors. However, the long-term emotional impact of being unable to have a child after cancer can be extremely distressing. Advances in knowledge about how cancer treatments may damage fertility, as well as newer techniques to preserve fertility, offer hope to patients who have not completed their childbearing at cancer diagnosis. Unfortunately, surveys in industrialised nations confirm that many cancer patients are still not informed about potential changes to their sexual function or fertility, and all modalities of fertility preservation remain underutilised. After cancer treatment, many patients continue to have unmet needs for information about restoring sexual function or becoming a parent. Although more research is needed on optimal clinical practice, current studies suggest a multidisciplinary approach, including both medical and psychosocial treatment options.

* *Corresponding author:* Tel.: +1 713 408 7219.
E-mail addresses: lschover@mdanderson.org (L.R. Schover), c.l.creutzberg@lumc.nl (C. Creutzberg).
http://dx.doi.org/10.1016/j.ejcsup.2014.03.004
1359-6349/

1. Introduction

Reproductive problems are among the most common and distressing consequences of cancer treatment. Infertility caused by cancer treatment only affects a minority of cancer patients, since most are beyond the age of wanting to have a child. Sexual dysfunction is a more universal threat. For most men and women, reproductive problems persist long after cancer treatment. We summarise the mechanisms of damage to reproductive health from cancer treatment and suggest ways to provide information and effective medical and psychosocial interventions to cancer patients and survivors. We also summarise recommendations for research and practice from the authors, who comprised a panel of experts at the first European Organisation for Research and Treatment of Cancer (EORTC) Survivorship Summit.

2. The prevalence of sexual dysfunction related to cancer

Close to two-thirds of cancer survivors in the United States were treated for pelvic or breast tumors [1], with at least a 50% prevalence of long-term, severe sexual dysfunction [2]. The situation is likely to be similar across Europe, given comparable prevalence and types of cancer [3]. Most sexual problems are not caused by the cancer itself, but by toxicities of cancer treatment [2]. Although sexual problems are more distressing for those under age 65 [4–6], and among patients who are sexually active at cancer diagnosis [7–10], sexuality remains important even for many geriatric cancer survivors [11,12]. Damage during cancer treatment to pelvic nerves, blood vessels, and organ structures leads to the highest rates of sexual dysfunction [10,11,13–20], but problems are common even after lung cancer [8,21], haematologic malignancies [22], or head and neck tumors [23]. Rates of sexual problems are close to 33% in survivors of childhood cancer, with women twice as likely as men to report dysfunction [24,25]. People treated for central nervous system tumors in childhood or adolescence may be limited in their adult relationships by learning disabilities and continued dependence on their families of origin [24]. In both men and women, other side effects of cancer treatment can lead to discontinuation of sexual activity, particularly persistent fatigue [26], nausea, or urinary and bowel incontinence [27–29].

2.1. *Sexual problems in men*

In men, the most common sexual problems are loss of desire for sex and erectile dysfunction (ED) [2]. Less common, but certainly distressing, are changes in the quality of orgasm, difficulties reaching orgasm, and pain with erection or orgasm [29,30]. Despite innovations such as laparoscopic robotic radical prostatectomy, few men recover normal erections after pelvic cancer surgery. Even among men who had excellent erections at baseline and are under age 65, fewer than 25% retain or recover their former erection quality [31–33]. Similarly, techniques to limit damage from radiation therapy have been disappointing, with little evidence of superior erectile function after intensity-modulated radiation therapy or proton therapy compared to computer guided external beam protocols [34–39], and disappointing long-term results after brachytherapy [20,34,39]. It is clear that a history of prostate cancer is a major predictor of sexual dysfunction, even for men on active surveillance. In the Scandinavian Prostate Cancer Group Study, at 12-year follow-up, 84% of men reported erectile dysfunction after radical prostatectomy, as did 80% on active surveillance, compared to only 43% of matched control men who had not had prostate cancer [40]. In the United States, the 10-year follow-up for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, revealed that over 95% of men in each prostate cancer treatment group had erection problems, again significantly worse than rates in controls [41]. Another prospective cohort study recently reported that by 15-yr follow-up, 87% of men with localised disease have erectile dysfunction [20].

Men who have surgery for bladder [42] or rectal cancer [14,43], or chemoradiation for anal cancer [44] also have high rates of ED. Sexual problems are not exclusive to men who have treatment to the pelvic organs. Hypogonadism and damage to pelvic nerves may lead to sexual dysfunction after intensive chemotherapy [26,45,46], or in men treated with either pelvic radiotherapy or total body irradiation [39,47,48]. Survivors of testis cancer or lymphoma also may have excess rates of sexual inactivity and low desire [49,50], though evidence remains equivocal [51]. Causes may be multifactorial, including hypogonadism, fatigue, and negative mood [45].

Animal studies suggest that obtaining erections several times a week by using treatments such as phosphodiesterase-5-inhibitors, penile injection therapy, or vacuum erection devices may protect the erectile tissue in the penis from atrophy, allowing better recovery of erections over time. Unfortunately, adherence to such treatments, often called penile rehabilitation, is so poor that it has been difficult to demonstrate clear benefit [52].

2.2. *Sexual problems in women*

In women the most common sexual problems are vaginal dryness and other genital changes that lead to pain during sexual activity, or loss of sexual desire, usually accompanied by difficulty feeling arousal and pleasure during sex [2]. Cancer treatments that increase the risk of sexual dysfunction for women include any that cause abrupt, premature ovarian failure in women who had not yet begun menopause [53,54]. Women whose combination chemotherapy leads to permanent ovarian failure seem to have a higher risk for sexual problems than those who continue to menstruate or have just a temporary cessation of menses [55,56]. The risk of permanent ovarian failure increases with the woman's age, especially for women over age 35, and with alkylating drugs and higher total doses of chemotherapy. As in men, any pelvic radiation therapy contributes strongly to the risk of sexual dysfunction, from a combination of ovarian failure and direct tissue damage to genital areas in the radiation field [11,19,39,57]. Use of gonadotropin agonists or antagonists to create a temporary state of ovarian failure also causes sexual problems, although the dysfunctions may resolve once hormonal therapy is discontinued [13]. Bilateral oophorectomy increases the prevalence of sexual dysfunction whether per-

formed as part of cancer surgery or as prophylactic surgery in women with genetic mutations that increase gynaecologic cancer risk [54]. Although oestrogen replacement helps somewhat with vaginal dryness, it does not restore normal sexual function [54]. Hormonal therapy also may cause sexual problems. Women given tamoxifen to prevent or treat breast cancer have negligible changes in sexual function if they did not have prior chemotherapy [53,55], but aromatase inhibitors may cause severe vaginal dryness and pain with sex [10,13]. At least a quarter of women who have systemic graft versus host disease after allogeneic stem cell or bone marrow transplantation develop irritation and then scarring on the vulva and in the vagina. If not treated early, genital graft versus host disease can make intercourse impossible, essentially obliterating a woman's vagina [58].

3. Communication about Sexual Function in Oncology Practice

Although most research on communication about sexuality between health care professionals (HCPs) and cancer patients is qualitative, or based on surveys with limited numbers of participants [59–61], results agree strongly on the major issues, across developed countries. Cancer patients want their HCPs to provide information and help with the sexual consequences of cancer treatment, but rarely receive such care [6,21,62]. HCPs believe that patients who want help with sexuality will bring up the topic themselves [61,63]. Some endorse the value of discussing sex with patients [63], but each profession—oncologists, nurses, mental health professionals—fails to take responsibility to provide such discussions, suggesting it is someone else's job [43,64,65]. Barriers to discussing sex cited by HCPs include lack of time, lack of knowledge, a lack of a network of specialists who can act as referrals, and personal discomfort with the topic of sexuality [63,43,66–68]. HCPs tend to be most reluctant to discuss sex with patients who are different from them, including opposite gender, different sexual orientation, the unmarried, the much younger or older, or patients from a different ethnicity or culture [61,64]. Patients want help with a broad array of sexual issues, not only including sexual function, but also self-concept and relationships, whereas most HCPs discuss sex at best in a narrow, medicalised fashion, focusing on problems such as erectile dysfunction or vulvovaginal atrophy that would prevent penile/vaginal intercourse [60,63,66,69–75]. HCPs report similar patterns of inadequate communication about sexual issues in other areas of care, such as cardiology [76], gynaecologic practice [77,78], general practice [79,80], or psychological practice [81].

4. Assessment of sexual function

Although erections and vaginal blood flow can be measured physiologically, most tests have limited relevance in clinical practice for diagnosing sexual dysfunction or in creating a treatment plan [82,83]. Since sexual desire, arousal, and pleasure are subjective, assessment of changes with cancer treatment often relies on interviews or patient-reported outcome questionnaires [84]. A variety of standardised questionnaires have been used to assess sexual function in oncology settings [84]. Some are specific to one type of cancer, such as the Expanded Prostate Cancer Index Composite (EPIC), which measures sexual function, urinary and bowel incontinence, and symptoms related to hormonal therapy [85]. The Female Sexual Function Index, a 19-item multiple-choice measure for women, has been validated for cancer patients [86]. In the United States, the National Cancer Institute has sponsored research to create brief screening questionnaires for cancer-related sexual dysfunction, as well as a larger bank of problem-specific items that researchers can utilise for a particular research project [69,87]. In Europe, the EORTC Quality of Life (QLG) Sexual health working group has begun qualitative and survey research to develop a more multifaceted Sexual Health Measure for cancer patients and cancer survivors that will include concepts such as body image, self-esteem, and relationship changes as well as assessing actual sexual function (Elfriede Griemel, PhD, personal communication).

5. Interventions for cancer-related sexual dysfunction

Fewer than 20% of most male or female cancer survivors seek professional care (psychological or medical) for their sexual problems [88–90], although close to half would like such help if it were accessible and affordable [88,89]. Over half of men who have radical prostatectomy get medical help for ED, but their rates are exceptional because of surgeons' attention to preserving erectile function through penile rehabilitation [62,91]. Sexuality is rated as a high priority issue by a quarter to three-quarters of survivors [23,62,69], and is ranked as an important unmet need during cancer survivorship [23,42,62,92,93]. Sexual dysfunction after cancer is consistently associated with poor perceived quality of life [5,15,17,93–96].

6. Rationale for a multidisciplinary approach

Research on interventions to improve sexual function and satisfaction in cancer patients and survivors suggests that a multidisciplinary approach, combining medical and psychosocial care, is the most effective strategy [2,97]. Although dysfunctions typically result from physiological damage related to cancer treatment, resuming a satisfying sex life requires good communication between partners [98], taking a view that sexual pleasure and intimacy may include a variety of activities besides penetrative intercourse [73,97–100], and being able to cope with the indignities and limitations of resuming sex after cancer. Providing information and counselling early in the process of treatment planning may be more effective than trying to restore sexual function after problems have become well-established [52,101].

Although a minority of men do try mechanical treatments for ED, satisfaction and adherence remain poor [90,97]. In the United States from 2003 to 2006, Medicare records of 39,000 men with localised prostate cancer showed that 26% used a phosphodiesterase-5-inhibitor after radical prostatectomy,

and only 9% did so after radiation therapy [91]. A number of studies show that men on adjuvant hormonal therapy are the least likely to use a medical treatment for erectile dysfunction. A review of surveys on erectile dysfunction treatment in prostate cancer survivors treated in academic medical centres suggests that 38–52% use oral medication, 7–18% use penile injection therapy, 5–19% use a vacuum erection device, 4–10% try a urethral suppository, and only 2% have penile prosthesis surgery [90,102–109]. Unfortunately, utilisation of these treatments is well below 50% after several months, except in men who have a penile prosthesis [110]. Barriers include the need to interrupt sexual activity, as well as limited partner acceptance.

Similarly, in women it is rare that simple use of vaginal dilation [111,112], lubricants [101], or oestrogen treatments [53,54,101,113] restore the vulva and vagina to a problem-free state. Vaginal dilation is best used as a preventive measure rather than to treat established vaginal atrophy, but it is difficult to convince women to use a dilator regularly [112]. However, innovative new vaginal moisturisers [114,115] and selective oestrogen receptor modifiers [116,117] may provide options to prevent and treat dyspareunia without increasing cancer risk, especially when combined with sexual counselling [113,118].

7. Structure of a sexuality clinic in oncology practice settings

One solution is better training for HCPs in general. A practical model could focus on training one or several team members (such as nurses, physician's assistants, social workers, or psychologists) in an oncology outpatient clinic to be the 'reproductive specialist' who can assess patients' concerns and provide educational resources and brief sexual counselling, using low intensity cognitive-behavioural therapy [119]. Patients who need more intensive medical treatment or cognitive behavioural sex therapy could then be referred to specialists.

Large cancer centres ideally should have in-house sexual dysfunction clinics including specialists in mental health, sexology, gynaecology, and urology, with outreach to cancer site-specific clinics across the institution to educate and encourage HCPs to ask about sexual issues, provide basic information, and make referrals. Such clinics are far from universally available, however. In community oncology offices or less specialised settings, such services are rarely available. At best, oncologists, gynaecologists and urologists provide purely medical suggestions and treatments. At least in the United States, as well as some European countries, poor insurance reimbursement for mental health care is a barrier to establishing counselling and supportive services. Furthermore, few mental health professionals who practice in oncology settings have expertise in treatment of sexual dysfunction. Conversely, most community-based specialists in sexual problems have little knowledge of oncology. Each practice setting should develop a referral network of in-house or community urologists, andrologists, and gynaecologists with expertise in treating medical aspects of sexual dysfunction.

Once a triage system is set up, with trained reproductive counsellors on the frontline and specialists available for referrals, sexual rehabilitation can become a routine part of quality care in oncology. Patients ideally should be informed about potential problems at the time of treatment planning. Further assessment of needs for help should take place at each follow-up visit. One attractive approach is to use electronic media to provide interactive, tailored education and counselling for patients [120], supplementing with human contact as needed [97,118]. When patients are treated at a tertiary referral centre away from home, telehealth options such as realtime online support groups or providing psychotherapy sessions via secure videochat may be helpful. Patients with chronically conflicted relationships [97] or complicated sexual histories [121] may need referral to a mental health professional with expertise in treating sexual dysfunction.

8. Priorities for research on sexuality and cancer

For too long, researchers have focused on defining the prevalence and types of sexual problems after various cancer treatments. Although some valuable work remains to be done on comparative effectiveness of cancer treatments that differ in their risk of reproductive side effects, the types of sexual problems that commonly occur and the cancer treatments that most increase risk for them are clear. The area that continues to be neglected is the design and evaluation of effective interventions to prevent or treat cancer-related sexual dysfunction. In particular, mental health and medical specialists need to collaborate to create cost-effective treatment programs to help prevent, or at least better manage, sexual problems that may interfere with adherence to life-saving cancer treatments, and that clearly damage quality of life in the long-term, even after successful cancer treatment. When helping patients make shared decisions about treatment options, a discussion of potential long-term sexual effects should be included. After evaluating and refining interventions, it will be important to study how best to disseminate and implement them so that they reach not only the affluent, educated patients treated at major urban cancer centres, but also the larger majority of people who rarely have adequate knowledge about cancer-related sexual problems, or skills for coping with them.

As part of the EORTC Survivorship Summit, our working group suggested the following high priority areas for research and future clinical services:

- Create and evaluate cost-effective programs of education and multidisciplinary treatment for sexual dysfunction that can be applied across a variety of oncology treatment settings
- Find ways to prevent cancer-related sexual dysfunction or at least provide early intervention to minimise problems

- Support the efforts of the EORTC QLG to create an instrument that will provide a comprehensive assessment of sexual issues important to cancer survivors, including physiological, psychological, and social aspects of sexuality.

9. The prevalence of cancer-related damage to fertility

Cancer patients aged 44 or less at diagnosis make up about 13% of newly diagnosed cases worldwide [122]. Although men 45 or older may still be interested in having future children [123], this is the age group most at risk for distress when childbearing is interrupted. Damage to fertility is usually linked to particular cancer treatments, but some types of cancer also may be associated with temporary or permanent subfecundity. For example, men with testicular cancer often have poor semen quality at diagnosis, and although most have better values after treatment, those initial semen analyses predict post-treatment sperm quality and genetic integrity [124]. Indeed the risk of several types of cancer is elevated in men with poor semen quality who present for infertility treatment [125]. In women, too, childlessness is associated with elevated risk of some types of ovarian cancer [126] and with hormone-sensitive breast tumors [127]. Women with mutations in the BRCA1 gene also may have a genetic risk for decreased ovarian reserve, leading to an earlier average age at menopause [128].

In general however, it is the treatments used for cancer that damage fertility. Chemotherapy regimens that include alkylating drugs are associated with the highest risk of infertility in both men and women, with damage to sperm or oocytes increasing with drug dose [129]. The testes are even more sensitive than the ovaries to damage from radiation therapy [130]. The mechanisms of damage to fertility may be similar for chemotherapy and for a significant dosage of radiation to the gonads [129,130]. In the ovaries, one recent theory is that the number of primordial follicles recruited for growth accelerates, ultimately resulting in apoptosis of successive waves of maturing oocytes, diminishing and ultimately eradicating the supply [131]. Blood flow to the ovaries has also been observed to decrease after some types of chemotherapy, and certainly decreases with tissue damage from radiation therapy [132]. Age is a greater factor in post-treatment fertility for women than for men with cancer [133]. When women reach their mid- to late thirties, oocytes are recruited and die at an accelerated rate, even without an environmental risk factor [132].

Because fertility preservation is a new option, with high costs and unknown long-term benefits, it would be helpful to have criteria to optimise patient selection. Levels of anti-müllerian hormone (AMH), a marker of the number of primordial follicles remaining in the ovaries, predict a woman's likelihood of having menstrual cycles after chemotherapy [133]. Very low levels of AMH are also associated with poor response to ovarian stimulation [134]. Obtaining AMH levels or using ultrasound imaging of the ovaries to examine volume and antral follicle counts may give some idea of an individual woman's ovarian reserve before or after cancer treatment, but neither measure is reliable enough to definitively guide decisions about whether a cycle of ovarian stimulation would be worthwhile [134]. Recently, concerns have been raised over the reliability of a new commercial AMH assay used in most clinical settings [135]. International standards for AMH values are also still lacking [134].

A woman's age, individual ovarian reserve, type and dose of chemotherapy and/or dose of radiation to the ovaries give a general idea of the likelihood that she will end up in permanent, premature ovarian failure after cancer treatment, but more prospective research is needed to develop predictive algorithms to use in individual clinical-decision making about fertility preservation [132–135]. Many women under age 35 at the time of cancer treatment will continue to menstruate or will recover menstrual cycles, but because their ovarian reserve has been depleted, they remain at significant risk to reach menopause years earlier than normal [132]. Furthermore, the presence of menstrual cycles has been used as the endpoint of much research on cancer and fertility, but is far from a guarantee that conception will be possible [132].

With data from a number of registry-based studies, becoming pregnant after completing cancer treatment does not appear to increase the risk of disease recurrence, even in women with hormone-positive breast cancer [136]. Occult damage to heart or lung function after a woman's cancer treatment may occasionally cause unexpected health problems during a pregnancy. More often, women have birth complications after cancer that include low birth weight infants, premature birth, miscarriage, or neonatal death, particularly in women who had uterine exposure to radiation in childhood [137].

For men, permanent infertility after cancer treatment results when all stem cells in the testes have been destroyed by either chemotherapy or radiation therapy [130,138]. About 3% to 18% of men are azoospermic at cancer diagnosis, before receiving any treatment [139]. Even if no sperm are found in a man's semen, islands of sperm production may remain. Exploration of the testes using microsurgery has allowed urologists to harvest mature sperm to use for cryopreservation before cancer treatment or for fertility treatment after cancer [139]. Recovery of spermatogenesis is common after chemotherapy or lower doses of radiation to the testes, but may take several years [130,138].

10. Health of children born to cancer survivors

Large studies of children born to parents who were treated for cancer before conception have largely been reassuring. No excess rate of congenital abnormalities or genetic disease has been found in offspring of childhood cancer survivors [140,141], or in the offspring of young adults treated for cancer [137]. Even most children exposed in utero to chemotherapy during a mother's cancer treatment for cancer appear to be healthy, as long as treatment is delayed until the second trimester of pregnancy [142].

11. Techniques of fertility preservation

Sperm banking has been available for post-pubertal men facing cancer treatment for decades, but became more widely

used after the advent of intracytoplasmic sperm injection in the early 1990s [130,138]. Even if only a few sperm cells with poor motility survived freezing and thawing, they could be used for conception with *in vitro* fertilisation. Still, records of utilisation of cryopreserved semen in many large registries continue to show that typically only about 10% to 20% of men retrieve their samples for infertility treatment [143]. Most men conceive using fresh sperm after cancer. Others die or decide not to have children. Although a number of cancer centres are cryopreserving small pieces of testicular tissue obtained from prepubertal boys who undergo cancer treatments with high risk of damaging fertility, we remain years away from having a way to use these samples for conception [130,138]. Human sperm cells have not yet been successfully matured *in vitro* or by autografting the tissue onto an immunodeficient mouse host. Autotransplantation of testicular tissue risks reintroducing cancer cells. A hope is that spermatogonial stem cells that manufacture sperm cells can be isolated and used to repopulate the cancer survivor's testis, but attempts have not been successful in humans [130].

Fertility preservation is even more complicated and expensive in women. For prepubertal girls, the only current option is again the experimental one of retrieving ovarian tissue for cryopreservation [144]. Later options would include autotransplantation of the thawed tissue, with its attendant risks of a cancer recurrence, or using primordial follicles with *in vitro* maturation, another procedure that is not yet technically possible, though advances are being made [145]. Recently, a live birth was reported after conception using a metaphase II oocyte harvested from the ovary of a young woman with ovarian cancer and matured *in vitro* before being fertilised in the laboratory [146]. Ovarian tissue cryopreservation is still considered experimental by the American Society of Reproductive Medicine [147], and autotransplantation of ovarian tissue has resulted in fewer than 30 live births worldwide [148]. It is now possible, however, to begin ovarian stimulation for fertility preservation at any point in the menstrual cycle with excellent results, so that the cycle can usually be accomplished in less than 2 weeks [149], minimising delays in starting cancer treatment. Since birth rates are now equal using cryopreserved oocytes subsequently thawed and fertilised, compared to those from using cryopreserved embryos, the options have increased for young cancer patients who are not in a stable relationship [148]. For women with breast cancer, protocols using letrozole as part of ovarian stimulation can minimise peak estradiol levels during fertility preservation without compromising results, potentially decreasing the risk that a cycle of hormone stimulation would lead to cancer recurrence [149].

Cancer treatments can sometimes be modified to spare fertility, for example avoiding the use of alkylating chemotherapy in treating Hodgkin lymphoma when the cancer prognosis is favourable [150,151]. When women are going to have pelvic radiotherapy, ovarian transposition (moving the ovaries out of the field to minimise their exposure) can often preserve hormonal function and fertility, though uterine capacity may still be damaged [152]. Other options that may be successful for both cancer treatment and fertility preservation include conisation for noninvasive cervical malignancies, trachelectomy for very early stage cervical cancer, which spare the uterus and ovaries [153], conservative surgery for germ cell, borderline, or early stage epithelial ovarian tumors [154], and treatment of early stage uterine cancer with progestogen therapy, followed by hysterectomy after pregnancy [155].

12. Utilisation of fertility preservation

Sperm banking, a relatively inexpensive and medically uncomplicated procedure, remains underutilised in industrialised nations [138,156], even in countries whose universal health system pays for sperm banking [157]. In a recent Swedish registry-based cohort, however, 68% of men recalled getting information on sperm banking and 54% preserved semen [158]. The most common barrier remains failure to get information to male patients in a timely way in oncology treatment settings [159]. The oncologist's recommendation is a crucial factor [155,156,159]. For teens, it is important to include the parents in the education and counselling as part of the decision process [160]. Despite relatively low rates of utilisation of banked semen, sperm banking remains a simple and effective type of fertility preservation. In a recent study of men treated for Hodgkin lymphoma, semen cryopreservation doubled the odds of fatherhood after treatment, with 20% of children conceived using cryopreserved semen [161].

Even fewer eligible women undergo some type of fertility preservation. The out-of-pocket costs to undergo ovarian stimulation or surgery to retrieve ovarian tissue for storage vary widely across the world. A high cost for *in vitro* fertilisation not only decreases the rate of usage in a nation's women, but also influences the number of embryos placed in a transfer cycle, with higher costs of care leading to the adverse outcome of more multiple births [162]. In the United States, where insurance rarely covers ovarian stimulation, only 12% of infertile women use any infertility services, with the great majority only having a medical consultation [163]. Women who use assisted reproductive technology are older, more affluent and educated, and more likely to be Caucasian [163]. These same demographic trends are seen in the small percentage of United States women with cancer who undergo fertility preservation [164–166]. Yet even in Canada, where fertility preservation is included in national health insurance, fewer than 5% of eligible women appear to have fertility preservation before cancer treatment [167]. In one academic centre in the Netherlands, only 2% of women had fertility preservation [168]. Young girls or adult women are less likely than men to be informed about fertility preservation [169]. In the same Swedish cohort with such high rates of sperm banking, only 12% of women had been offered fertility preservation and 2% proceeded [158]. Some women could only have a biological child with the help of a gestational carrier, but restrictive laws in many European states forbid such arrangements, leaving opportunities only for those wealthy enough to afford reproductive 'tourism,' with the added concern of exploitation of women living in poverty [170].

13. Information, decisional support, and counselling about fertility preservation

Surveys of adolescents and young adults with cancer show that a majority want information on damage to fertility and

options for parenthood, particularly those who have not yet begun having children [151,171–176]. Despite guidelines on counselling patients about fertility preservation originally published in 2006 by the American Society of Clinical Oncology, two surveys conducted several years later found than fewer than half of oncologists in the United States were making routine referrals [177,178]. In a recent survey of 100 oncologists in the United Kingdom, only 38% routinely provided written material on fertility preservation to eligible patients [179]. Despite a national system of sperm banking for oncology patients in the United Kingdom, 21% of cancer specialists who responded to a survey were unfamiliar with local policies, and many let their own beliefs influence which men they referred [180]. In a study of French oncologists, 54% had not referred a single female patient for fertility preservation in the past 6 months [181]. Common barriers found in research on oncologist communication include lack of time in busy clinics, lack of knowledge about fertility preservation, and not knowing how or where to refer patients. In addition, many oncologists do not discuss fertility preservation if they believe a patient would not be able to afford it financially, or if a patient has a poor prognosis or already has at least one child.

Some evidence already suggests that having the opportunity to consider fertility preservation and to make an informed decision can improve well-being in cancer survivors [182]. Actually storing reproductive material helps patients feel more optimistic about the future [182,183]. A survey of young women treated for cancer, 10 years after their diagnosis, revealed that those who had wanted a child and were unable subsequently to fulfil their desire remained significantly distressed about infertility [184]. Childless women were affected the most severely. A recent survey of young cancer survivors in Germany also found unmet needs for information and lingering distress, especially in women [185].

Because decisions about preserving fertility are complex and usually must be made within a narrow window of time that is already extremely stressful because of the unexpected diagnosis of cancer, efforts are being made to create educational materials and decision aids for patients [186–189]. Although the science of decision-making in health settings is advancing, few studies have evaluated the long-term outcomes of decision-aids on cancer patients' well-being [190]. More work is needed to find the best ways to educate patients about cancer-related infertility and to help them make choices that will improve their future satisfaction with life.

14. Parenthood options after successful cancer treatment

The major focus of research on fertility and cancer has been on modalities to prevent damage from cancer treatment. However, as illustrated above, the majority of cancer survivors who want to have children do not have cryopreserved genetic material. Women may want evaluation of their current ovarian reserve to help in deciding whether to try to conceive naturally, pursue assisted reproductive technology, or consider social parenthood by means of donated oocytes or embryos, or adoption [132,184]. Men often have not had a recent semen analysis, and are unsure whether they could father a pregnancy [143]. Although cancer survivors express more comfort with adoption than with using donor sperm or oocytes [171,172], their medical history may be a barrier to adopting in many international or domestic contexts [191]. One solution would be a multidisciplinary clinic that could assess current fertility in cancer survivors, offer appropriate options for fertility treatment, and also provide education and counselling on options to become a parent or to resolve grief about cancer-related infertility.

15. Priorities for research and clinical services regarding cancer and fertility

The working group suggests the following priorities related to cancer and fertility:

- Establish a European registry, including biomarkers that could be used to predict infertility in response to specific cancer treatments. Include periodic standardised surveys about clinical services such as counselling and referral regarding fertility preservation
- Create tools to facilitate shared decision-making for patients who are at risk for infertility from cancer treatment
- Create multidisciplinary programs to assess fertility after cancer treatment, help patients to make decisions about parenthood, and to offer a range of options for patients to become parents.

Conflict of interest statement

None declared.

REFERENCES

[1] American Cancer Society. Cancer treatment and survivorship facts & figures 2012–2013. Atlanta: American Cancer Society; 2012.
[2] Sadovsky R, Basson R, Krychman M, Morales AM, Schover L, Wang R, et al. Cancer and sexual problems. J Sex Med 2010;7(1 Pt 2):349–73.
[3] Rowland JH, Kent EE, Forsythe LP, Håvard Loge J, Hjorth L, Glaser A, et al. Cancer survivorship research in Europe and the United States: where have we been, where are we going, and what can we learn from each other? Cancer 2013;Suppl. 119:2094–108.
[4] Hall AE, Boyes AW, Bowman J, Walsh RA, James EL, Girgis A. Young adult cancer survivors' psychosocial well-being: a cross-sectional study assessing quality of life, unmet needs, and health behaviors. Support Care Cancer 2012;20:1333–41.
[5] Li WW, Lam WW, Au AH, Ye M, Law WL, Poon J, et al. Interpreting differences in patterns of supportive care needs between patients with breast cancer and patients with colorectal cancer. Psychooncology 2013;22:792–8.
[6] McCallum M, Lefebvre M, Jolicoeur L, Maheu C, Lebel S. Sexual health and gynecological cancer: conceptualizing patient needs and overcoming barriers to seeking and

accessing services. J Psychosom Obstet Gynaecol 2012;33:135–42.
[7] Knight SJ, Latini DM. Sexual side effects and prostate cancer treatment decisions: patient information needs and preferences. Cancer J 2009;15:41–4.
[8] Reese JB, Shelby RA, Abernethy AP. Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. Support Care Cancer 2011;19:161–5.
[9] Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD. Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU Int 2012;109:1366–74.
[10] van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH et al. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer 2013, November 24 [Epublication ahead of print].
[11] Milbury K, Cohen L, Jenkins R, Skibber JM, Schover LR. The association between psychosocial and medical factors with long-term sexual dysfunction after treatment for colorectal cancer. Support Care Cancer 2013;21:793–802.
[12] Puts MT, Papoutsis A, Springall E, Tourangeau AE. A systematic review of unmet needs of newly diagnosed older cancer patients undergoing active cancer treatment. Support Care Cancer 2012;20:1377–94.
[13] Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–8.
[14] Den Oudsten BL, Traa MJ, Thong MS, Martijn H, De Hingh IH, Bosscha K, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer 2012;48:3161–70.
[15] Froeding LP, Ottosen C, Rung-Hansen H, Svane D, Mosgaard BJ, Jensen PT. Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study. J Sex Med 2013, November 29 [Epublication ahead of print].
[16] Hedgepeth RC, Gilbert SM, He C, Lee CT, Wood Jr DP. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology 2010;76:671–5.
[17] Kyrdalen AE, Dahl AA, Hernes E, Småstuen MC, Fosså SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221–32.
[18] Le Borgne G, Mercier M, Woronoff AS, Guizard AV, Abeilard E, Caravati-Jouvenceaux A, et al. Quality of life in long-term cervical cancer survivors: a population-based study. Gynecol Oncol 2013;129:222–8.
[19] Lind H, Waldenström A-C, Dunberger G, Al-Abany M, Alevronta E, Johansson KA, Olsson C, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer 2011;104:737–45. PMCID: PMC3171018.
[20] Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–45.
[21] Lindau ST, Surawska H, Paice J, Baron SR. Communication about sexuality and intimacy in couples affected by lung cancer and their clinical-care providers. Psychooncology 2011;20:179–85. PMCID: PMC3319754.
[22] Thygesen KH, Schjødt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant 2012;47:716–24.
[23] Henry M, Habib LA, Morrison M, Yang JW, Li XJ, Lin S et al. Head and neck cancer patients want us to support them psychologically in the posttreatment period: Survey results. Palliat Support Care 2013, October 24 [Epublication ahead of print].
[24] Bober SL, Zhou ES, Chen B, Manley PE, Kenney LB, Recklitis CJ. Sexual function in childhood cancer survivors: a report from Project REACH. J Sex Med 2013;10:2084–93.
[25] Zebrack BJ, Foley S, Wittmann D, Leonard M. Sexual functioning in young adult survivors of childhood cancer. Psychooncology 2010;198:814–22.
[26] Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006;107:2949–57.
[27] Dunberger G, Lind H, Steineck G, Waldenström AC, Nyberg T, Al-Abany M, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer 2010;46:606–15. PMID: 19926277.
[28] Tekkis PP, Cornish JA, Remzi FH, Tilney HS, Strong SA, Church JM, et al. Measuring sexual and urinary outcomes in women after rectal cancer excision. Dis Colon Rectum 2009;52:46–54. PMID: 19273955.
[29] Frey AU, Sønksen J, Fode M. Neglected side effects after radical prostatectomy: a systematic review. J Sex Med 2013, November 25 [Epublication ahead of print].
[30] Barnas JL, Pierpaoli S, Ladd P, Valenzuela R, Aviv N, Parker M, et al. The prevalence and nature of orgasmic dysfunction **after** radical prostatectomy. BJU Int 2004;94:603–5.
[31] Dalkin BL, Christopher BA. Potent men undergoing radical prostatectomy: a prospective study measuring sexual health outcomes and the impact of erectile dysfunction treatments. Urol Oncol 2008;26:281–5. http://www.sciencedirect.com/science/article/pii/S1078143907000671#.
[32] Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, et al. Factors predicting early and late phase decline of sexual health related quality of life following radical prostatectomy. J Sex Med 2011;8:2935–43.
[33] Nelson C, Scardino PT, Eastham JA, Mulhall JP. Back to baseline: erectile function recovery after radical prostatectomy from the patients' perspective. J Sex Med 2013;6:1636–43. PMID: 23551767.
[34] Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012;61:112–27. PMID: 22001105.
[35] Lilleby W, Stensvold A, Dahl AA. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life. Prostate 2013;73:1038–47. PMID:23532709.
[36] Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012;18(307):1611–20. PMID:23532709.
[37] Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2011;81:e325–334. PMID: 21498008.

[38] Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, et al. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2012;82:e765–771. PMID: 22300559.
[39] Incrocci L, Jensen PT. Pelvic radiotherapy and sexual function in men and women. J Sex Med 2013;10(Suppl. 1):53–64. PMID: 23387912.
[40] Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, SPCG-4 Investigators, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891–9.
[41] Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2012;30:2768–75.
[42] Mohamed NE, Chaoprang Herrera P, Hudson S, Revenson TA, Lee CT, Quale DZ et al. Muscle invasive bladder cancer: examining survivors' burden and unmet needs. J Urol 2013, July 30 [Epublication ahead of print] PMID: 23911603.
[43] Traa MJ, De Vries J, Roukema JA, Rutten HJ, Den Oudsten BL. The sexual health care needs after colorectal cancer: the view of patients, partners, and health care professionals. Support Care Cancer 2013, November 18 [Epublication ahead of print].
[44] Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol 2013;52:736–44.
[45] Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, et al. Do male lymphoma survivors have impaired sexual function? J Clin Oncol 2009;27:6019–26.
[46] Aksoy S, Harputluoglu H, Kilickap S, et al. Erectile dysfunction in successfully treated lymphoma. Support Care Cancer 2008;16:291–7.
[47] Yau I, Vuong T, Garant A, Ducruet T, Doran P, Faria S, et al. Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:1481–6. PMID: 19147304.
[48] Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, et al. The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2013;85:e15–19. PMCID: PMC3578309.
[49] Tal R, Stember DS, Logmanieh N, Narus J, Mulhall JP. Erectile dysfunction in men treated for testicular cancer. BJU Int 2013. http://dx.doi.org/10.1111/bju.12331 [Epub ahead of print].
[50] Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 2013;109:60–7.
[51] Recklitis CJ. Sanchez Varela V, Ng A, Mauch P, Bober S. Sexual functioning in long-term survivors of Hodgkin's lymphoma. Psychooncology 2010;19:1229–33.
[52] Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med 2013;10:195–203.
[53] Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008;26:753–8. PMID: 18258983.
[54] Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl). 2012;8:543–55. http://www.futuremedicine.com/doi/abs/10.2217/whe.12.41?url_ver=Z39.88-2003&rfr_id= ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov&.
[55] Bober SL, Giobbie-Hurder A, Emmons KM, Winer E, Partridge A. Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med 2013;10:370–7.
[56] Ochsenkühn R, Hermelink K, Clayton AH, von SV, Gallwas J, Ditsch N. Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder. J Sex Med 2011;8:1486–94.
[57] Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D. Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiation Oncol 2010;5:41–9. PMCID: PMC2883545.
[58] Hirsch P, Leclerc M, Rybojad M, Petropoulou AD, Robin M, Ribaud P, et al. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. Transplantation 2012;93:1265–9.
[59] Carr S. Communication about sexuality and cancer. In: Mulhall JP, editor. Cancer and sexual health. New York: Humana Press; 2011. p. 307–16.
[60] Fitch MI, Beaudoin G, Johnson B. Challenges having conversations about sexuality in ambulatory settings: part II–health care provider perspectives. Can Oncol Nurs J 2013;23:182–96.
[61] Hordern AJ, Street AF. Constructions of sexuality and intimacy after cancer: patient and health professional perspectives. Soc Sci Med 2007;64:1704–18.
[62] Flynn KE, Reese JB, Jeffery DD, Abernethy AP, Lin L, Shelby RA, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 2012;21:594–601. PMCID: PMC3149787.
[63] Ussher JM, Perz J, Gilbert E, Wong WK, Mason C, Hobbs K, et al. Talking about sex after cancer: a discourse analytic study of health care professional accounts of sexual communication with patients. Psychol Health 2013;28:1370–90.
[64] Julien JO, Thom B, Kling NE. Identification of barriers to sexual health assessment in oncology nursing practice. Oncol Nursing Forum 2010;37:E186–190.
[65] Takahashi M, Kai I, Hisata M, Higashi Y. Attitudes and practices of breast cancer consultations regarding sexual issues: a nationwide survey of Japanese surgeons. J Clin Oncol 2006;24:5763–8.
[66] Platano G, Margraf J, Alder J, Bitzer J. Psychosocial factors and therapeutic approaches in the context of sexual history taking in men: a study conducted among Swiss general practitioners and urologists. J Sex Med 2008;5:2533–56.
[67] Parish S, Clayton AH. Sexual medicine education: review and commentary. J Sex Med 2007;4:259–68.
[68] Zeng YC, Li Q, Wang N, Ching SS, Loke AY. Chinese nurses' attitudes and beliefs toward sexuality care in cancer patients. Cancer Nurs 2011;34:E14–20.
[69] Flynn KE, Jeffery DD, Keefe FJ, Porter LS, Shelby RA, Fawzy MR, et al. Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). Psychooncology 2011;20:378–86.
[70] de Vocht H, Hordern A, Notter J, Van de Wiel H. Stepped skills: A team approach towards communication about sexuality and intimacy in cancer and palliative care. Austral Med J 2011;4:610–9.
[71] Dyer K, das Nair R. Why don't healthcare professionals talk about sex? A systematic review of recent qualitative studies conducted in the United Kingdom. J Sex Med 2012, July 30 [Epublication ahead of print].

[72] Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012;109:98–103.
[73] Reese JB, Keefe FJ, Somers TJ, Abernethy AP. Coping with sexual concerns after cancer: the use of flexible coping. Support Care Cancer 2010;18:785–800.
[74] Thompson K, Dyson G, Holland L, Joubert L. An exploratory study of oncology specialists' understanding of the preferences of young people living with cancer. Soc Work in Health Care 2013;52:166–90.
[75] White ID, Faithfull S, Allan H. The re-construction of women's sexual lives after pelvic radiotherapy: a critique of social constructionist and biomedical perspectives on the study of female sexuality after cancer treatment. Soc Sci Med 2013;76:186–96.
[76] Nicolai MP, Both S, Liem SS, Pelger RC, Putter H, Schalij MJ, et al. Discussing sexual function in the cardiology practice. Clin Res Cardiol 2013;102:329–36.
[77] Lamont J. Female sexual health consensus clinical guidelines. J Obstet Gynaecol Can 2012;34:769–75.
[78] Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don't talk about when we don't talk about sex: results of a national survey of U.S. obstetrician/gynecologists. J Sex Med 2012;9(5):1285–94.
[79] Abdolrasulnia M, Shewchuk RM, Roepke N, Granstaff US, Dean J, Foster JA, Goldstein AT, et al. Management of female sexual problems: perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. J Sex Med 2010;7:2499–508.
[80] Jiwa M, O'Shea C, Merriman G, Halkett G, Spilsbury K. Psychosexual problems in general practice: measuring consultation competence using two different measures. Qual Prim Care 2010;18:243–60.
[81] Miller SA, Byers ES. Practicing psychologists' sexual intervention self-efficacy and willingness to treat sexual issues. Arch Sex Behav 2012;41:1041–50.
[82] Ghanem H, Shamloul R. An evidence-based perspective to commonly performed erectile dysfunction investigations. J Sex Med 2008;5:1582–9.
[83] Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013;100:898–904.
[84] Althof SE, Parish SJ. Clinical interviewing techniques and sexuality questionnaires for male and female cancer patients. J Sex Med 2013;10(Suppl 1):35–42.
[85] Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, PROST-QA Consortium, et al. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 2014;191:638–45.
[86] Baser RE, Li Y, Carter J. Psychometric validation of the female sexual function index (FSFI) in cancer survivors. Cancer 2012;118:4606–18.
[87] Flynn KE, Lin L, Cyranowski JM, Reeve BB, Reese JB, Jeffery DD, et al. Development of the NIH PROMIS® sexual function and satisfaction measures in patients with cancer. J Sex Med 2013;10(Suppl. 1):43–52.
[88] Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, et al. Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer 2011;117:2643–51. PMCID: PMC3084902.
[89] Huyghe E, Sui D, Odensky E, Schover LR. Needs assessment survey to justify establishing a reproductive health clinic at a comprehensive cancer center. J Sex Med 2009;6:149–63.
[90] Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002;95:2397–407.
[91] Prasad MM, Prasad SM, Hevelone ND, et al. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer. J Sex Med 2010;7:1062–73.
[92] Holm LV, Hansen DG, Johansen C, Vedsted P, Larsen PV, Kragstrup J, et al. Participation in cancer rehabilitation and unmet needs: a population-based cohort study. Support Care Cancer 2012;20:2913–24. PMCID: PMC3461205.
[93] Park BW, Hwang SY. Unmet needs and their relationship with quality of life among women with recurrent breast cancer. J Breast Cancer 2012;15:454–61.
[94] Adams E, Boulton MG, Horne A, Rose PW, Durrant L, Collingwood M et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol) 2013, August 28 [Epublication ahead of print].
[95] Hansen DG, Larsen PV, Holm LV, Rottmann N, Bergholdt SH, Søndergaard J. Association between unmet needs and quality of life of cancer patients: a population-based study. Acta Oncol 2013;52:391–9.
[96] Juraskova I, Bonner C, Bell ML, Sharpe L, Robertson R, Butow P. Quantity vs. quality: an exploration of the predictors of posttreatment sexual adjustment for women affected by early stage cervical and endometrial cancer. J Sex Med 2012;9:2952–60.
[97] Schover LR, Canada AL, Yuan Y, Sui D, Neese L, Jenkins R, et al. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 2012;118:500–9. http://onlinelibrary.wiley.com/doi/10.1002/cncr.26308/abstract;jsessionid=2900A2D001128F022CF37E12CA7DB985.f04t02.
[98] Perz J, Ussher JM, Gilbert E. Constructions of sex and intimacy after cancer: Q methodology study of people with cancer, their partners, and health professionals. BMC Cancer 2013;13:270.
[99] Beck AM, Robinson JW, Carlson LE. Sexual values as the key to maintaining satisfying sex after prostate cancer treatment: the physical pleasure—relational intimacy model of sexual motivation. Arch Sex Behav 2013;42:1637–47.
[100] Gilbert E, Ussher JM, Perz J. Renegotiating sexuality and intimacy in the context of cancer: the experiences of carers. Arch Sex Behav 2010;39:998–1009.
[101] Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8:549–59.
[102] Salonia A, Gallina A, Zanni G, Briganti A, Dehò F, Saccà A, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;53:564–70. PMID: 17761385.
[103] Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. J Urol 2009;182:649–54. PMID: 19535108.
[104] Stephenson RA, Mori M, Hsieh Y-C, Beer TM, Stanford JL, Gilliland FD, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the surveillance, epidemiology, and end results prostate cancer outcomes study. J Urol 2005;174:646–50. PMID: 16006930.
[105] Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, Bowden CH, et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol 2013;189:2229–36. PMID: 23219537.
[106] Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361–9. PMID 22616766.

[107] Conaglen HM, Conaglen JV. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J Sex Med 2012;9:857–65. PMID 22239731.
[108] Derouet H, Caspari D, Rohde V, Rommel G, Ziegler M. Treatment of erectile dysfunction with external vacuum devices. Andrologia 1999;31(Suppl 1):85–94. PMID: 10643525.
[109] Dutta TC, Eid JF. Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999;54:691–3. PMID: 10565753.
[110] Tal R, Jacks LM, Elkin E, Mulhall JP. Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. J Sex Med 2011;8:1797–804. PMID: 21426495.
[111] Brand AH, Do V, Stenlake A. Can an educational intervention improve compliance with vaginal dilator use in patients treated with radiation for a gynecological malignancy? Int J Gynecol Cancer 2012;22:897–904.
[112] Cullen K, Fergus K, Dasgupta T, Fitch M, Doyle C, Adams L. From, "sex toy" to intrusive imposition: a qualitative examination of women's experiences with vaginal dilator use following treatment for gynecological cancer. J Sex Med 2012;9:1162–73.
[113] Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive–emotional factors, and dyadic adjustment. J Sex Med 2012;9:2066–76.
[114] Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet 2013;288:1199–201.
[115] Coste I, Judlin P, Lepargneur JP, Bou-Antoun S. Safety and efficacy of an intravaginal prebiotic gel in the prevention of recurrent bacterial vaginosis: a randomized double-blind study. Obstet Gynecol Int 2012;2012:147867.
[116] Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2013, November 20 [Epublication ahead of print].
[117] Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause 2013, June 18 [Epublication ahead of print].
[118] Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efficacy trial of an internet-based intervention for cancer-related female sexual dysfunction. J Natl Compr Canc Netw 2013;11:1389–97. PMCID: in process.
[119] Giesler RB, Given B, Given CW, Rawl S, Monahan P, Burns D, et al. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention. Cancer 2005;104:752–62.
[120] Weinrich S, Koch M, Champion V, Leykin Y, Thekdi SM, Shumay DM, et al. Internet interventions for improving psychological well-being in psycho-oncology: review and recommendations. Psychooncology 2012;21:1016–25. PMCID: PMC3181007.
[121] Coker AL, Follingstad D, Garcia LS, Williams CM, Crawford TN, Bush HM. Association of intimate partner violence and childhood sexual abuse with cancer-related well-being in women. J Womens Health (Larchmt) 2012;21:1180–8.
[122] International Agency for Research on Cancer. GLOBOCAN 2012. Available from: http://globocan.iarc.fr; 2012 [cited 1 February 2014].
[123] Salonia A, Capogrosso P, Castiglione F, Russo A, Gallina A, Ferrari M, et al. Sperm banking is of key importance in patients with prostate cancer. Fertil Steril 2013;100:367–72.
[124] Bujan L, Walschaerts M, Moinard N, Hennebicq S, Saias J, Brugnon F, et al. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertil Steril 2013;100:673–80.
[125] Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz LI. Increased risk of cancer among azoospermic men. Fertil Steril 2013;100:681–5.
[126] Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet 2013:2871187–204.
[127] Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 2014 Jan 30. [Epub ahead of print].
[128] Tea MK, Weghofer A, Wagner K, Singer CF. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age. Maturitas. 2013;75(2):148–51.
[129] Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134–40.
[130] Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril 2013;100:1180–6.
[131] Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle 2013;12:3245–6.
[132] Hyman JH, Tulandi T. Fertility preservation options after gonadotoxic chemotherapy. Clin Med Insights Reprod Health 2013;7:61–9.
[133] Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013;49(16):3404–11.
[134] Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014, Jan 29 [Epub ahead of print].
[135] Rustamov O, Smith A, Roberts SA, Yates AP, Fitzgerald C, Krishnan M, et al. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod 2012;27:3085–91.
[136] Azim Jr HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013;31:73–9.
[137] Stensheim H, Klungsøyr K, Skjaerven R, Grotmol T, Fosså SD. Birth outcomes among offspring of adult cancer survivors: a population-based study. Int J Cancer 2013;133:2696–705.
[138] Wang JH, Muller CH, Lin K. Optimizing fertility preservation for pre- and postpubertal males with cancer. Semin Reprod Med 2013;31(4):274–85. http://dx.doi.org/10.1055/s-0033-1345275 [Epub 2013 Jun 17].
[139] Berookhim BM, Mulhall JP. Outcomes of operative sperm retrieval strategies for fertility preservation among males scheduled to undergo cancer treatment. Fertil Steril 2014, Jan 11 [Epub ahead of print].
[140] Signorello LB, Mulvihill JJ, Green DM, Munro HM, Stovall M, Weathers RE, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 2012;30:239–45.
[141] Winther JF, Olsen JH, Wu H, Shyr Y, Mulvihill JJ, Stovall M, et al. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol 2012;30:27–33.

[142] Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs 2013;15:329–34.
[143] Pacey AA, Merrick H, Arden-Close E, Morris K, Barton LC, Crook AJ, et al. Monitoring fertility (semen analysis) by cancer survivors who banked sperm prior to cancer treatment. Hum Reprod 2012;27(11):3132–9.
[144] Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertil Steril 2013;99:1503–13.
[145] Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. American Society of Clinical Oncology Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500–10.
[146] Prasath EB, Chan ML, Wong WH, Lim CJ, Tharmalingam MD, Hendricks M, et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod 2014;29:276–8.
[147] Nogueira D, Sadeu JC, Montagut J. In vitro oocyte maturation: current status. Semin Reprod Med 2012;30(3):199–213.
[148] Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril 2013;99:1476–84.
[149] Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013;100:1681–5.
[150] van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168–79.
[151] van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser LC, et al. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol 2012;30:3854–63.
[152] Irtan S, Orbach D, Helfre S, Sarnacki S. Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol 2013;14:e601–608.
[153] Pareja R, Rendón GJ, Sanz-Lomana CM, Monzón O, Ramirez PT. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy – a systematic literature review. Gynecol Oncol 2013;131:77–82.
[154] Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol 2013, Dec 13 [Epub ahead of print].
[155] Hubbs JL, Saig RM, Abaid LN, Bae-Jump VL, Gehrig PA. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol 2013;121:1172–80.
[156] Pacey AA, Eiser C. The importance of fertility preservation in cancer patients. Expert Rev Anticancer Ther 2014, Feb 9 [Epub ahead of print].
[157] Yee S, Buckett W, Campbell S, Yanofsky RA, Barr RD. A national study of the provision of oncology sperm banking services among Canadian fertility clinics. Eur J Cancer Care (Engl) 2013;22:440–9.
[158] Armuand GM, Rodriguez-Wallberg KA, Wettergren L, Ahlgren J, Enblad G, Höglund M, et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 2012;30:2147–53.
[159] Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol 2002;20:1890–7.
[160] Ginsberg JP, Ogle SK, Tuchman LK, Carlson CA, Reilly MM, Hobbie WL, et al. Sperm banking for adolescent and young adult cancer patients: sperm quality, patient, and parent perspectives. Pediatr Blood Cancer 2008;50:594–8.
[161] van der Kaaij MAE, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, et al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.. Hum Reprod 2014;29:525–33.
[162] Chambers GM, Hoang VP, Sullivan EA, et al. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis. Fertil Steril 2014;101:191–8.
[163] Chandra A, Stephen EH. Infertility service use among U.S. women: 1995 and 2002. Fertil Steril 1995;2010(93):725–36.
[164] Letourneau JM, Smith JF, Ebbel EE, et al. Racial, soioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer 2012;118:4579–88.
[165] Goodman LR, Balthazar U, Kim J, Mersereau JE. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod 2012;27:2076–81.
[166] Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril 2012;97:671–6.
[167] Yee S, Buckett W, Campbell S, Yanofsky R, Barr RD. A national study of the provision of oncofertility services to female patients in Canada. J Obstet Gynaecol Can 2012;34:849–58.
[168] Jenninga E, Hilders CG, Louwe LA, Peters AA. Female fertility preservation: practical and ethical considerations of an underused procedure. Cancer J 2008;14:333–9.
[169] Kohler TS, Kondapalli LA, Shah A, et al. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. J Assist Reprod Genet 2011;28:269–77.
[170] Ramskold LA, Posner MP. Commercial surrogacy: how provisions of monetary remuneration and powers of international law can prevent exploitation of gestational surrogates. J Med Ethics 2013;39:397–402.
[171] Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer 1999;86:697–709.
[172] Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002;20:1880–9.
[173] Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174–83.
[174] Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 2005;23:766–73.
[175] Burns KC, Boudreau C, Panepinto JA. Attitudes regarding fertility preservation in female adolescent cancer patients. J Pediatr Hematol Oncol 2006;28:350–4.
[176] Oosterhuis BE, Goodwin T, Kiernan M, Hudson MM, Dahl GV. Concerns about infertility risks among pediatric oncology patients and their parents. Pediatr Blood Cancer 2008;50:85–9.

[177] Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril 2010;94:1652–6.
[178] Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol 2009;27:5952–7.
[179] Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. Br J Cancer 2013;108:1602–15.
[180] Gilbert E, Adams A, Mehanna H, Harrison B, Hartshorne GM. Who should be offered sperm banking for fertility preservation? A survey of UK oncologists and haematologists. Ann Oncol 2011;22:1209–14.
[181] Préaubert L, Poggi P, Pibarot M, Delotte J, Thibault E, Saias-Magnan J, et al. Fertility preservation among patients with cancer: report of a French regional practical experience. J Gynecol Obstet Biol Reprod (Paris) 2013;42:246–51.
[182] Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012;118:1710–7.
[183] Saito K, Suzuki K, Iwasaki A, Yumura Y, Kubota Y. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer 2005;104:521–4.
[184] Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psychooncology 2012;21:134–43.
[185] Geue K, Richter D, Schmidt R, Sender A, Sidentopf F, Brähler E, Stöbel-Richter Y. The desire for children and fertility issues among young German cancer survivors. J Adolesc Health 2013, Dec 3 [Epub ahead of print].
[186] Nagel K, Wizowski L, Duckworth J, Cassano J, Hahn SA, Neal M. Using plain language skills to create an educational brochure about sperm banking for adolescent and young adult males with cancer. J Pediatr Oncol Nurs 2008: 25220–6.
[187] Huyghe E, Martinetti P, Sui D, Schover LR. Banking on fatherhood: pilot studies of a computerized educational tool on sperm banking before cancer treatment. Psychooncology 2009;18:1011–4.
[188] Garvelink MM, ter Kuile MM, Fischer MJ, Louwé LA, Hilders CG, Kroep JR, et al. Development of a decision aid about fertility preservation for women with breast cancer in The Netherlands. J Psychosom Obstet Gynaecol 2013;34:170–8.
[189] Peate M, Meiser B, Cheah BC, Saunders C, Butow P, Thewes B, et al. Making hard choices easier: a prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. Br J Cancer 2012;106:1053–61.
[190] Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;1:CD001431.
[191] Rosen A. Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005;34: 91–3.